The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2018 | UK-based CLL trials to look out for at ASH 2018
A number of UK-based clinical trials in the chronic lymphocytic leukemia (CLL) space will have updates at the upcoming American Society of Hematology (ASH) 2018 Annual Meeting and Exposition. Here, Peter Hillmen, MD, ChB, of Leeds Teaching Hospital NHS Trust, Leeds, UK, discusses the CLARITY trial of ibrutinib and venetoclax for relapsed/refractory CLL, and the FLAIR trial of ibrutinib-containing regimens, including ibrutinib and venetoclax, in the frontline setting (ISRCTN01844152), which will both have updates at ASH 2018. This video was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
